Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eylea Biosimilar Developer Momenta To Be Acquired By J&J For $6.5bn

M710 Aflibercept Candidate To Be Filed In 2021

Executive Summary

Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.

You may also be interested in...



Dealmaking Quarterly Statistics, Q3 2020

During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials

Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.

Momenta And Sandoz Pay $120m To Settle Enoxaparin Suit

Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel